# ‚öîÔ∏è CLINICAL TRIAL DOSSIER

**NCT ID**: NCT05562479  
**Trial Title**: Effect of Sars-cov-2 on Donor Oocyte Quality and Quantity, a Multicenter Retrospective Study.  
**Patient ID**: ayesha_001  
**Generated**: 2025-11-14T19:56:29.521443  
**Generated By**: JR2 (Dossier Sidekick)

---

## 1. TRIAL OVERVIEW

**Title**: Effect of Sars-cov-2 on Donor Oocyte Quality and Quantity, a Multicenter Retrospective Study.  
**Phase**:   
**Status**: COMPLETED  
**Sponsor**:   
**Estimated Enrollment**: 0  
**Primary Endpoint**: None

**ClinicalTrials.gov**: https://clinicaltrials.gov/study/NCT05562479

---

## 2. ELIGIBILITY ASSESSMENT

**Summary**: 4/5 criteria met

### Eligibility Criteria Table

| Criterion | Status | Confidence | Notes |
|-----------|--------|------------|-------|
| Disease Match | ‚úÖ PASS | 0.90 | Ovarian/gynecologic match: ["ovarian reserve", "sars-cov-2 infection", "blastocyst"] |
| Treatment Line | ‚úÖ PASS | 0.80 | Line match assumed (not explicitly excluded) |
| Biomarker Requirements | ‚úÖ PASS | 1.00 | No biomarker requirements |
| Location (NYC Metro) | ‚úÖ PASS | 0.50 | No location data (assume match) |
| Inclusion Criteria (Full Text Available) | üìã REVIEW | 0.80 | See full text: Inclusion

* Age: 18 - 32 Years
* Body Mass Index between 18 and 26
* AFC: Antral follicular count over 15 in total.
* AMH: Anti-Mullerian hormone over 2.5
* Signed consents.
* Covid vaccines and infe... |

---

## 3. STRATEGIC SCENARIOS

### Best Case

**Eligibility Probability**: 80.0%

**Scenario**: All pending biomarker tests return favorable results

**Eligibility Level**: HIGH

### Most Likely

**Eligibility Probability**: 80.0%

**Scenario**: 50% of pending tests pass, some may require additional screening

**Eligibility Level**: MODERATE

### Challenge

**Eligibility Probability**: 80.0%

**Scenario**: Some pending tests fail, may need alternative trials

**Eligibility Level**: LOW

---

## 4. TACTICAL RECOMMENDATIONS

| Action | Lab | Cost | Timeline | Priority | Rationale |
|--------|-----|------|----------|----------|----------|
| Proceed with trial enrollment | N/A | N/A | Immediate | HIGH | All eligibility criteria met |

---

## 5. DRUG MECHANISMS

### Sars

**Mechanism (Technical)**: [NEEDS VERIFICATION] Mechanism not found in database for Sars

**Mechanism (Layman)**: [NEEDS VERIFICATION] Please consult oncologist for mechanism explanation.

**Evidence Tier**: UNKNOWN

---

## 6. LOCATION DETAILS

No location data available.

---

## 7. TIMELINE

**Study Start Date**: 

**Primary Completion Date**: 

---

## 8. FULL ELIGIBILITY TEXT

### Inclusion Criteria

Inclusion

* Age: 18 - 32 Years
* Body Mass Index between 18 and 26
* AFC: Antral follicular count over 15 in total.
* AMH: Anti-Mullerian hormone over 2.5
* Signed consents.
* Covid vaccines and infection information (for case group).

Exclusion:

* Egg donors with incomplete information of days of stimulation, average dose of gonadotropins, the number of retrieved oocytes, mature oocytes, fertilised oocytes and top-quality embryos obtained.
* Familial genetic disorders.
* Menstrual cycle disorders.
* Polycystic ovary syndrome.

### Exclusion Criteria

N/A

---

## 9. CONTACT INFORMATION

Contact information not available.

---

## 10. PROVENANCE

**Generated By**: JR2

**Data Sources**: SQLite, Diffbot, DRUG_MECHANISM_DB

**Confidence Flags**: [INFERRED], [NEEDS VERIFICATION]

---

**RESEARCH USE ONLY (RUO)** - This dossier is for research purposes only and should not be used for clinical decision-making without proper medical review.

